PFS Non-inferior with Fixed-Duration Treatment with Venetoclax-Obinutuzumab or Venetoclax-Ibrutinib to Continuous Ibrutinib in Patients with Previously Untreated CLL By Ogkologos - December 17, 2025 5 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the interim analysis of the CLL17 study Source RELATED ARTICLESMORE FROM AUTHOR Patient Guide on Cancer Pain Management Now Available Also in French FDA Approves Pembrolizumab with Enfortumab Vedotin-ejfv for Muscle Invasive Bladder Cancer Postneoadjuvant Trastuzumab Deruxtecan Results in Higher Likelihood of iDFS Among Patients with HER2-positive EBC with Residual Invasive Disease After Neoadjuvant Treatment MOST POPULAR After A Long And Dangerous Battle, Africa Has Been Declared Free... August 26, 2020 Sacituzumab Govitecan Demonstrates Overall Survival Benefit Over Chemotherapy in Patients with... September 18, 2023 Perioperative Durvalumab Plus Neoadjuvant Chemotherapy Improves EFS and OS in Cisplatin-Eligible... November 18, 2024 Study Finds Most Women Who ‘Go Flat’ After Mastectomy Are Happy... January 16, 2021 Load more HOT NEWS Immune cell count could determine whether chemotherapy is required in oropharyngeal... Using a Blood Test to Select Treatments for Advanced Gastrointestinal Stromal... Makeup Artist Gives Breast Cancer Survivors Free Makeovers Single-Fraction SABR Preferred from Resource and Patient Perspectives for Pulmonary Oligometastases
